ALTIUM
18.2.2020 15:32:10 CET | Business Wire | Press release
EMBEDDED WORLD — Today Altium, a global leader in PCB design software, announced the launch of a new cloud-based application that redefines the way that printed circuit board designs are shared between designers, part suppliers, and manufacturers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005188/en/
The A365 Viewer, powered by the Altium 365 cloud platform, is a brand new, and innovative way to view and share electronic designs through a browser on any web-enabled desktop, phone or tablet. Schematics, PCB layout, and 3D visualization provide an interactive eCAD experience with no downloads or installations required. The A365 Viewer is part of Altium’s cloud strategy and newly launched Altium 365 cloud platform.
Simplicity is the Ultimate Sophistication
Until now, designers have been forced to share their PCB designs through PDFs or static images. With the new A365 Viewer, an interactive experience is created that retains all of the key relevant information that's typically lost when sharing static files. For example, the A365 Viewer allows users to search for, select, cross-probe and inspect components and nets while moving seamlessly between schematic, PCB and 3D views of their board.
Using the A365 Viewer requires no CAD tools or experience. The A365 Viewer is designed to work with multiple eCAD formats, currently supporting Autodesk® Eagle™ and Altium Designer™. Other popular PCB design software formats will be supported in the near future.
Easily Embedded on Your Website
Anyone can easily embed the viewer on their website, free of charge, by visiting https://www.altium.com/viewer/ . As an example, a well-known developer of electronics hardware and software kits, Arduino, is helping engineers and makers to easily and quickly visualize the PCB designs and assemblies available in their product kits, by embedding the A365 Viewer on the Arduino website .
"Adding the Altium 365 Viewer has significantly enhanced the user experience when navigating the product documentation in our website. Now Arduino users can freely browse schematics, PCB layout and even 3D models of the Arduino boards and modules online, without the need to download or install anything additional. The capability of being CAD-agnostic will shorty allow Arduino to add the online design viewer to every product page, including the ones designed in Autodesk Eagle. " - Fabio Violante, CEO, Arduino
Built-in Design IP Protection
The A365 Viewer protects the IP rights of design owners while retaining the CAD design details via a new process called Published Design Impression (PDI). The Viewer processes the design source files to create a Published Design Impression, or PDI. The PDI is a CAD-aware, perishable snapshot of the design that captures limited information such as components, net connectivity and basic geometrics, excluding design primitive data that would be required to fully comprehend and author changes to the design.
The design sources are discarded immediately after being used solely for the purpose of creating a PDI. The design is available for the duration of the user’s browser session and is automatically removed when the browser tab is closed.
Altium is demonstrating its A365 Viewer at the Embedded World 2020 trade show, Hall 4 stand 371, taking place at the Nuremberg Exhibition Center on February 25-27. To learn more visit: https://www.altium.com/viewer/
ABOUT ALTIUM
Altium LLC (ASX:ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005188/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom